Departments of Renal Medicine, Rare Diseases and Molecular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy.
Front Immunol. 2021 Jun 30;12:711915. doi: 10.3389/fimmu.2021.711915. eCollection 2021.
Passive antibody therapy has been used to treat outbreaks of viral disease, including the ongoing pandemic of severe respiratory acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) or COVID-19. However, the real benefits of the procedure are unclear. We infused a concentrated solution of neutralizing anti-SARS-CoV-2 antibodies obtained from a convalescent donor with a single session of double filtration plasmapheresis (DFPP) into a 56-year-old woman with long history of unremitting, severe COVID-19. She was unable to establish an adequate antiviral immune response because of previous chemotherapy, including the infusion of the anti-CD20 monoclonal antibody rituximab, administered to treat a diffuse large B-cell lymphoma. The disease promptly recovered despite evidence of no endogenous anti-SARS-CoV-2 antibody production. The observation that passive antibody therapy might prove particularly effective in immunodepressed COVID-19 patients requires evaluation in prospective randomized controlled trial.
被动抗体疗法已被用于治疗病毒性疾病的爆发，包括目前严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）或 COVID-19 的大流行。然而，该程序的实际益处尚不清楚。我们将从恢复期供体中获得的浓缩中和抗 SARS-CoV-2 抗体溶液通过单次双滤过血浆置换（DFPP）输注到一名 56 岁的女性，她患有长期持续的严重 COVID-19。由于先前的化疗，包括输注抗 CD20 单克隆抗体利妥昔单抗，用于治疗弥漫性大 B 细胞淋巴瘤，她无法建立足够的抗病毒免疫反应。尽管没有内源性抗 SARS-CoV-2 抗体产生的证据，但疾病迅速恢复。观察到被动抗体疗法在免疫抑制的 COVID-19 患者中可能特别有效，需要在前瞻性随机对照试验中进行评估。
Zotero 插件
